Login to Your Account



Lemtrada’s sBLA Submission for MS Faces Major Issues

By Peter Winter
BioWorld Insight Editor

Friday, November 8, 2013
The FDA released its briefing documents in advance of the Peripheral and Central Nervous System Drugs Advisory Committee meeting Nov. 13. The committee will discuss the supplemental biologics license application (sBLA) for Lemtrada (alemtuzumab) injection, submitted by Genzyme Corp., a Sanofi SA company, for use in multiple sclerosis (MS).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription